With our recently developed in vitro physiologically based kinetic (PBK) modelling approach, we could extrapolate in vitro toxicity data to human toxicity values applying PBK-based reverse dosimetry. Ideally information on kinetic differences among human individuals within a population should be considered. In the present study, we demonstrated a modelling approach that integrated in vitro toxicity data, PBK modelling and Monte Carlo simulations to obtain insight in interindividual human kinetic variation and derive chemical specific adjustment factors (CSAFs) for phenol-induced developmental toxicity. The present study revealed that UGT1A6 is the primary enzyme responsible for the glucuronidation of phenol in humans followed by UGT1A9. Monte Carlo simulations were performed taking into account interindividual variation in glucuronidation by these specific UGTs and in the oral absorption coefficient. Linking Monte Carlo simulations with PBK modelling, population variability in the maximum plasma concentration of phenol for the human population could be predicted. This approach provided a CSAF for interindividual variation of 2.0 which covers the 99th percentile of the population, which is lower than the default safety factor of 3.16 for interindividual human kinetic differences. Dividing the dose-response curve data obtained with in vitro PBK-based reverse dosimetry, with the CSAF provided a dose-response curve that reflects the consequences of the interindividual variability in phenol kinetics for the developmental toxicity of phenol. The strength of the presented approach is that it provides insight in the effect of interindividual variation in kinetics for phenol-induced developmental toxicity, based on only in vitro and in silico testing.
obtained with the embryonic stem cell test (EST) (Strikwold et al. 2013 (Strikwold et al. , 2016 . Within this approach in vitro toxicity data obtained with the EST, quantifying the inhibition of differentiation of ES-D3 cells into beating cardiomyocytes by the test compound, were extrapolated to in vivo dose-response curves for developmental toxicity using in vitro PBK-based reverse dosimetry (Louisse et al. 2010 (Louisse et al. , 2014 Strikwold et al. 2013 Strikwold et al. , 2016 . The EST was previously developed and validated as a sensitive in vitro assay for embryogenesis/developmental toxicity in vivo (Genshow et al. 2004) . PoDs, in this case the BMDL 05 for developmental toxicity for the rat predicted with PBK-based reverse dosimetry, which can be used as a starting point in the hazard and risk assessment of chemicals, were less than 4-fold lower than the PoDs that were derived from in vivo developmental toxicity studies of phenol for the rat obtained from the literature (Strikwold et al. 2013 (Strikwold et al. , 2016 . Similar promising results were obtained when applying this approach for a series of glycol ethers and for all-trans-retinoic-acid (Louisse et al. 2010 (Louisse et al. , 2014 .
A major advantage of this in vitro PBK-based reverse dosimetry approach is that it provides the opportunity to make predictions directly for humans by taking PBK model parameters defined for humans into account. This implies that the in vitro PBK-based reverse dosimetry approach is not only relevant to reduce animal experiments but also to make the risk assessment more relevant to the human situation. Such human predictions are an important goal within the framework for toxicity testing in the 21th century as envisioned by the National Research Council (2007) .
Within our recent work, we made predictions on developmental toxicity of phenol for an average human female, applying the in vitro PBK-based reverse dosimetry approach for phenol (Strikwold et al. 2013) . However, this model did not take into account interindividual human variation in sensitivity towards the toxic effects, which may occur as a result of differences in kinetic processes between individuals. Although a default safety factor of 3.16 for interindividual human differences is often applied to account for such human variation in kinetics (IPCS 2005) , having more detailed insights in possible interindividual variation might provide risk assessors with a reliable basis to derive human guidance values and assist in defining chemical specific adjustment factors (CSAFs).
The aim of the present study was to demonstrate an approach that integrates in vitro toxicity data, PBK modelling and Monte Carlo simulations to assess the effects of human interindividual variation in kinetics for phenol-induced developmental toxicity.
Results from a previously published PBK model for phenol indicated that the glucuronidation pathway is an important determinant for blood phenol concentrations (Strikwold et al. 2013) . UDP-glucuronosyltransferase (UGT) 1A6 and UGT1A9 are likely to be involved in the glucuronidation of phenol because many p-substituted phenols are a substrate for these UGT forms (Ethell et al. 2002) . The sensitivity analysis of the PBK model for phenol (Strikwold et al. 2013) revealed that the oral absorption coefficient (ka) and glucuronidation of phenol in the liver were parameters that influenced the maximum predicted phenol plasma concentration (C max ) to a major extent and were therefore included in the evaluation of interindividual variation in the present study.
Our previously published human PBK model for unconjugated phenol (Strikwold et al. 2013 ) was used in the present study. Compartments that are included in this PBK model are the liver, small intestine, kidney and lungs, venous and arterial blood, and a compartment lumping the rest of the body tissues. The liver, small intestine and kidney were identified as metabolising organs for the human PBK model, modelling sulfation and glucuronidation of phenol. Kinetic studies in pregnant rats indicated that simple phenolic compounds may readily pass the placental barrier and that foetal and maternal plasma levels for phenol are quite similar (Abu-Qare et al. 2000; Gray and Kavlock 1990) . The concentration reaching the embryo was therefore set equal to maternal plasma concentration and no separate embryonic compartment was distinguished. This choice was also supported by our recently published PBK model for phenol (Strikwold et al. 2016 ) whose sensitivity analysis indicated that parameters related to the foetal/placental compartment (such as the volume of the placenta, blood flow to the placenta, and placental transfer) do not highly influence the fetal plasma concentrations of phenol. The performance of the human PBK model could not be evaluated due to the lack of data on the disposition of phenol in humans, but our PBK model for the rat which has a similar model structure was evaluated with in vivo plasma concentration-time data indicating that the model accurately predicts the time course of changes in plasma concentrations of phenol (Strikwold et al. 2013) . A detailed model description including the model algorithms and evaluation of the model performance is published in Strikwold et al. (2013) . General Outline Modelling Approaches. To enable prediction of the effect of interindividual human kinetic variation in sensitivity to phenol-induced developmental toxicity, information on the metabolic variation in phenol glucuronidation was generated with in vitro kinetic experiments using two approaches. At first, phenol glucuronidation was quantified using subcellular liver fractions of 10 female individuals. The kinetic constants obtained for each female were used to define 10 subject specific PBK models based on our previously developed PBK model for phenol (Strikwold et al. 2013) , from which differences in plasma phenol levels of the 10 individuals were calculated. Secondly, a Monte Carlo simulation was performed to predict interindividual variation in phenol plasma levels. To this end the variation in phenol glucuronidation was modelled based on data from in vitro kinetic experiments using UGT isoforms and human variation in expression of these UGT enzymes described in literature. In a next step interindividual variation for the oral absorption coefficient, which according to the sensitivity analysis (Strikwold et al. 2013 ) also highly influenced the model outcome, was included in the Monte Carlo simulations as well. Based on the results obtained from the latter Monte Carlo simulation a CSAF (IPCS 2005) was derived that accounts for interindividual differences in phenol kinetics within the human population. Possible consequences of the results obtained for risk assessment are discussed.
MATERIALS AND METHODS

Compounds and Biological Materials
Glucuronidation of Phenol by Pooled Female Human Liver Microsomes and Individual Female Human Liver S9. Incubations were performed to determine the kinetic constants, namely the maximum enzyme reaction rate (V max ) and the Michaelis-Menten constant (K m ) for phenol glucuronidation with female human liver fractions. The incubation mixtures consisted of 50 mM Tris-HCl buffer (pH 7.4) with 10 mM MgCl 2 , containing (final concentrations) 10 mM UDPGA, 0.5 mg microsomal protein/ml for assays with pooled female human liver microsomes or 0.5 mg S9 protein/ml for assays with 10 individual female human liver S9 homogenates. The incubation mixtures were pre-treated with the poreforming peptide alamethicin (0.025 mg/ml) added from a 200 times concentrated stock solution in methanol for 15 min on ice, to reduce the latency of UGTs enabling UDGPA to reach the active site in the in vitro system, thereby obtaining more physiologically relevant in vivo predictions of glucuronidation (Miners et al. (2006) ; Lin and Wong (2002) . Then, incubations were started after a 1-min pre-incubation at 37 C by the addition of the substrate phenol (final concentrations ranging from 200 to 4000 mM added from 200 times concentrated stock solutions in DMSO) and left in a shaking water bath of 37 C for 10 min for the assays with pooled female human liver microsomes and with individual female human liver S9. The reactions were terminated with the addition of ice-cold acetonitrile (20% v/v) and subsequently put on ice. In the blank incubation mixtures, UDPGA was omitted. The 10 human individual liver fractions were assumed to represent the female fertile population. To enable the collection of 10 female samples, also females aged 57 and 66 year were included, knowing that older age does not affect glucuronidation activity (Court 2010 ).
Glucuronidation of Phenol by Recombinant UGT Enzymes. Supersomes TM with individually expressed UGT enzymes 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15, 2B17 were screened on the ability to glucuronidate phenol. Incubations were performed in 50 mM Tris-HCl buffer (pH 7.4 including 10 mM MgCl 2 ), containing (final concentrations) 0.5 mg protein/ml and 10 mM UDPGA. To overcome enzyme latency the incubation mixtures were pre-treated for 15 min on ice, with the poreforming peptide alamethicin (0.025 mg/ml) added from a 200 times concentrated stock solution in methanol. Then, incubations were started after a 1-min preincubation at 37 C by the addition of phenol (final concentration 1000 mM added from a 200 times concentrated stock solution in DMSO) and left in a shaking water bath of 37 C for 45 min. The reactions were terminated with the addition of icecold acetonitrile (20% v/v) and subsequently put on ice. In the blank incubation mixtures UDPGA was omitted. Kinetic constants V max , K m , the inhibition constant K i or k, the latter representing the first-order kinetic rate constant in the absence of saturation (for details see section Enzyme kinetic parameters) were determined for those UGT enzymes that showed a sufficient turn-over in the screening study, including UGT1A6, UGT1A7, UGT1A8, UGT1A9, and UGT2B7. The final phenol concentrations ranged from 200 to 8000 mM depending on the UGT enzyme studied and were added to the incubation mixtures from 200 times concentrated stock solutions in DMSO. Other incubation conditions were similar as used for the screening assay, except that the incubation period was 30 min. Based on the kinetic curves and the kinetic constants obtained together with the scaled catalytic efficiency (V max /K m ), the contribution of the different UGTs to phenol glucuronidation in vivo was further evaluated and UGTs that were expected to contribute the most to phenol glucuronidation at relevant plasma concentrations of phenol were included in the Monte Carlo evaluation.
Relative Activity Factor (RAF). With the RAF approach (Crespi 1995 ) the glucuronidation activity of UGT enzymes can be scaled to female human liver microsomes enabling extrapolation of the in vitro determined activity to in vivo values. The V max values obtained from the in vitro incubations with recombinant enzymes (nmol/min/mg protein) were scaled to the in vivo situation (mmol/h/g organ) using this RAF approach (Crespi 1995) , according to the following equation:
in which MPL represents the microsomal protein yield of 32 mg/ (g liver) (Barter et al. 2007) . RAF UGT corresponds to the ratio between the conversion of an enzyme specific probe substrate by pooled female human liver microsomes (HLM) and by recombinant enzymes (Supersomes TM ). The RAF is determined according to the following equation:
in which, v represents the metabolic turnover of an enzyme specific probe substrate. The probe used to determine the RAF for UGT1A6 was serotonin (Krishnaswamy et al. 2003 ) and the probe for UGT1A9 was propofol (Court 2005) . To determine the RAF values for UGT1A6 and UGT1A9, incubations were performed as described for phenol glucuronidation using HLM or the Supersomes TM (both pre-treated with alamethicin to reduce enzyme latency), using a concentration of 0.1 mg protein/ml for HLM and 0.1 mg protein/ml for Supersomes TM for serotonin with an incubation time of 30 min, and a concentration of 0.1 mg protein/ml for HLM and 0.1 mg protein/ml for Supersomes TM for propofol with an incubation time of 15 min. The applied final probe concentrations in the incubations were 4000 mM for serotonin and 25 mM for propofol, taking into account recommendations about appropriate probe concentrations reported by Court (2005) . In the blank incubation mixtures, UDPGA was omitted. The performance of the RAF approach was evaluated by comparing the sum of scaled catalytic efficiencies (V max /K m ) of the individual isoenzymes UGT1A6 and UGT1A9 to the scaled catalytic efficiency that was determined with kinetic constants obtained from pooled female human liver microsomes.
Quantification of Compounds and Glucuronide Conjugates. Samples of the incubations with phenol, propofol and serotonin as substrate were centrifuged at 14 000 rpm for 5 min. Subsequently 3.5 ml were analysed by UPLC-PDA (Waters Acquity) according the method for phenol and phenylglucuronide described previously by Strikwold et al. (2013) . Phenylglucuronide was quantified by its peak area using a linear calibration curve (R 2 > 0.999) made using a commercially available reference compound. Chromatogram peaks of propofol glucuronide and serotonin glucuronide from samples of the incubation experiments were identified using commercially available reference standards. The RAFs were calculated based on the peak areas of the glucuronides that were formed after incubating the probes.
Enzyme Kinetic Parameters. Kinetic parameters describing enzymatic conversions were defined based on the in vitro metabolism data obtained in the present study using GraphPad (GraphPad Prism 5.0 software, San Diego, CA, USA). The best model fit was selected from the Michaelis-Menten model, substrate inhibition model, and linear curve fitting based on visual inspection of the curves. Subsequently, the relevant enzyme kinetic parameters (V max for the maximum enzyme reaction rate, Michaelis-Menten constant K m , inhibition constant K i or k representing the first-order kinetic rate constant) were estimated. In vitro derived V max(app) values were scaled to the in vivo situation using a protein yield of 32 mg/g liver (Barter et al. 2007 ) for in vitro studies with microsomes and Supersomes TM and 143 mg/g liver (Medinsky et al. 1994) for in vitro studies with S9. In vivo K m values were assumed to be the same as K m values obtained from the in vitro experiments. The catalytic efficiencies of the enzyme were defined by V max /K m .
PBK Models, Monte Carlo Simulations and Sensitivity Analysis. Our previously developed PBK model for phenol in humans (Strikwold et al. 2013 ) was used as starting point in the present study to evaluate the effect of human interindividual variation in kinetics for phenol-induced developmental toxicity. The kinetic constants derived in the present study from incubations with the pooled human female liver samples were used in the PBK model. Subsequently, a sensitivity analysis was performed using the same approach as described by Strikwold et al. (2013) to determine parameters that influenced the model outcome. Then, interindividual variability in phenol glucuronidation was assessed using a population of 10 female individuals. To this purpose, the kinetic constants (V max and K m ) for liver glucuronidation obtained from incubations with individual female human liver S9 homogenates were included in the PBK model for phenol (Strikwold et al. 2013) . With the PBK models, maximum phenol plasma concentrations (C max ) at an oral dose level of 25 mg/kg bw were calculated for each individual. The oral dose of 25 mg/kg bw was applied because this dose closely corresponds to the human BMDL 05 for developmental toxicity that was predicted in our previously published human PBK model for phenol (Strikwold et al. 2013) . C max was used because the BMDL 05 values predicted in our previous study with PBK-based reverse dosimetry using C max values of the concentrationreponse data of the EST as a dose metric corresponded better to the in vivo developmental toxicity values of phenol than extrapolations based on the Area Under the Concentrations time curve (AUC) of the EST (Strikwold et al. 2013 (Strikwold et al. , 2016 .
To enable prediction of kinetic variation in a larger human population, interindividual variability was assessed by linking the PBK model for phenol (Strikwold et al. 2013) with Monte Carlo simulations. To this end, a PBK model was developed in which the kinetic constants for glucuronidation of phenol were described with the kinetic constants obtained in the present study from incubations with recombinant UGT enzymes. Together with literature reporting human variation in expression of these UGT enzymes, Monte Carlo simulations could be performed on interindividual human differences in glucuronidation of phenol in the liver. The Monte Carlo simulations were performed in connection with the PBK model to simulate phenol plasma concentrations that could occur in the human female population at an oral dose of 25 mg/kg bw, when taking interindividual human variation in the maximum glucuronidation rate (V max ) of phenol in the liver into account. The predicted variation in the C max of phenol at an oral dose level of 25 mg/kg bw obtained with the Monte Carlo simulation was compared with the C max values of phenol predicted by the individual PBK models for the 10 individuals at an oral dose level of 25 mg/kg bw. So far, only variation in phenol glucuronidation was taken into account in both approaches, next to the use of average values for the other model parameters.
In addition to the analysis above, a Monte Carlo simulation was performed that in addition to variation in UGT expression, also included the interindividual human variation in the oral absorption coefficient (ka), because the sensitivity analysis revealed this to be another parameter of major influence (Strikwold et al. 2013) .
For the Monte Carlo modelling, a total of 10 000 simulations were performed. The distributions were truncated at 6 3 SD by excluding individuals with a V max value for UGT1A6 and/or UGT1A9 and/or a ka value higher or lower than three times the SD of the geometric mean values from the Monte Carlo simulation. This resulted in a final population of 9956 and 9907 individuals for, respectively, simulations with variation in UGTs and simulations with variation in both UGTs and ka. In each simulation, the values of the model parameters V max for UGT1A6 and UGT1A9 and the ka were randomly taken from the log-normal distribution. The log-normal distribution of a parameter was defined by the mean (m W ) and the standard deviation (r W ) according the equations defined by Zhang et al. (2007) :
where m X represents the average of V max_UGT or ka and CV x is the coefficient of variation for each of the values. In the simulation, the parameters were allowed to vary independently from one another. The average ka value was 7.62/h which was obtained from the rat in situ intestinal perfusion study of Humphrey et al. (1980) and assumed to be applicable for human. The average value for the apparent V max of UGT1A6 and UGT1A9 were experimentally obtained in the present study amounting 7.3 and 9.7 nmol/min/mg protein, respectively. The coefficients of variation (CV) representing interindividual variation in the glucuronidation activity by UGT1A6 and UGT1A9 amounting to 76% and 55%, respectively, were taken from the literature (Court 2010) and attributed to the V max values of these UGTs in the PBK model. The CV for ka was assumed to be 30% representing a moderate level of variation (Covington et al. 2007 ).
Model predictions with Monte Carlo simulations were performed with Berkeley Madonna (version 8.3.18, UC Berkeley, CA, USA). The population distribution generated with the Monte Carlo simulation was statistically analysed with GraphPad (GraphPad Prism 5.0 software, San Diego, CA, USA) to calculate the geometric mean, and different percentiles of the C max values of phenol obtained from the Monte Carlo analysis. The population distribution enabled the prediction of the CSAF, which was obtained by dividing the percentile (90th and 99th of the population) of C max by the geometric mean of C max (IPCS 2005) .
Reverse Dosimetry and Dose-Response Analysis. In analogy to our previous study (Strikwold et al. 2013) , reverse dosimetry was applied using the maximum plasma concentration (C max ) as appropriate dose metric. To this end each effect-concentration (EC x ) tested in the murine EST, which corresponds to a phenol concentration that results in a certain level of inhibition of differentiation of ES-D3 cells into beating cardiomyocytes, was set equal to the maximum plasma concentration of unconjugated phenol in the PBK model for the average female that used kinetic constants determined using pooled female liver samples, providing effective external oral dose levels (ED x ) (Strikwold et al. 2013) . From these ED x values, an in vivo dose-response curve was derived and a 95% lower confidence limit of the benchmark dose at 5% benchmark response (BMDL 05 ) using the Benchmark Dose Software (BMDS) version 2.6 from the Environmental Protection Agency (EPA). Calculations were performed with the logProbit model because this model provided the best fit for our previously predicted dose-response curve for phenol in humans (Strikwold et al. 2013 ). Subsequently, the dose-response curve of a sensitive individual in the population, represented by the 99th percentile obtained from the Monte Carlo simulations, was visualised by applying the CSAF (99th percentile of C max ) to the dose-response curve of the average population, assuming linear kinetic processes at these dose levels.
RESULTS
Formation of Phenylglucuronide by Pooled Female
Human Liver Microsomes and Individual Female Human Liver S9 Table 1 presents the kinetic constants K m , V max and the scaled catalytic efficiencies for glucuronidation as obtained in incubations with pooled female human liver microsomes and individual female liver S9 preparations. The K m and V max for the glucuronidation of phenol obtained with pooled female microsomes were 771 mM and 64 mmol/h/g liver, respectively.
The average K m and V max of the 10 individuals amounted to 976 mM and 78 mmol/h/g liver, respectively. The difference between the highest and lowest K m value predicted for the 10 females is 4.8-fold. Interestingly, the K m value of individual H_217 is 257 mM which is relatively low compared with the K m values obtained with the pooled females (K m ¼ 771 mM) and the K m values obtained with the other individual liver samples (mean K m ¼ 976 mM). The difference between the highest and lowest scaled V max values of the individuals is 2.3-fold. The mean scaled V max of the 10 individuals is reasonably in accordance with the scaled V max obtained from incubations with pooled female liver microsomes, namely 78 versus 64 mmol/h/g liver, respectively. The kinetic constants obtained for the 10 females were used in the PBK models for the individuals, of which the model predictions were used to assess the consequences of interindividual differences in glucuronidation of phenol for the resulting C max values.
The coefficients of variation (CVs) of the in vitro determined V max and K m of the 10 individuals were 32% and 30%, respectively, and the resulting CV for the scaled catalytic efficiency (V max/ K m ) of the 10 females was 79%. This relative high CV for the scaled catalytic efficiency is caused by female H_217 which has a relative low K m value of 257 mM, but a V max value comparable to the other individuals. Removing this subject from the dataset provides a CV of 36% for the scaled catalytic efficiency, hence providing a moderate variation in glucuronidation activity for the individuals.
Formation of Phenylglucuronide by Recombinant UGT Enzymes
Incubations with cDNA recombinant expressed UGT enzymes were performed to determine which UGT enzymes are able to glucuronidate phenol. Figure 1 presents the formation of phenol glucuronide for each tested UGT during 45 min of incubation under similar conditions. Especially, UGT1A6 and UGT1A9 were able to form phenylglucuronide, followed by UGT2B7. Extrahepatic UGT1A7, UGT1A8 and UGT1A10, which are amongst others differentially expressed in oesophagus, stomach, small intestine, colon, bile duct, lung, and kidney (Tukey and Strassburg 2000; Ohno and Nakajin 2009) , were also able to glucuronidate phenol, as well as UGT1A1 and UGT2B15. Each of these extrahepatic UGTs and UGT1A1 and 2B15 showed a conversion that was lower than 5% of the sum of phenylglucuronide formed by all individual tested UGTs, under similar screening conditions. Glucuronidation of phenol was not detected for UGT1A3, UGT1A4, UGT2B4, UGT2B10, and UGT2B17 during the 45 min of incubation.
Determination of the contribution of each individual UGT in vivo required a correction of V max of each UGT by the respective RAF. To determine the V max and other kinetic values, the rate of glucuronidation by UGT1A6, UGT1A7, UGT1A8, UGT1A9, and UGT2B7 with increasing concentrations of phenol was determined of which the results are presented in Figure 2 . The kinetic constants V max , K m , K i , and k, together with the RAFs and the (scaled) catalytic efficiencies of the UGTs are presented in Table 2 . The RAFs determined in the present study for UGT1A6 and UGT1A9 were 3.4 and 0.57, respectively. The RAF for UGT2B7, which is an average of three RAF values from literature is 1.7 (Al-Subeihi et al. 2015; Kato et al. 2012; Saabi et al. 2013 ). At present no specific probes for UGT1A7, UGT1A8 and UGT1A10 are available, which hampers determination of RAFs for these enzymes. As the metabolic conversion by these enzymes is observed to be lower than for UGT1A6 and UGT1A9 (i.e. lower catalytic efficiency) and as UGT1A7, UGT1A8, and UGT1A10 are only present in extrahepatic tissues these enzymes were not included in the PBK model to evaluate interindividual differences using Monte Carlo simulations. UGT2B7 did not show saturation kinetics, and showed a linear increase in the rate of glucuronidation with an increasing phenol concentration up to at least 8000 mM. Taking into account the relatively low scaled catalytic efficiency of 1.44 ml/h/g liver for UGT2B7 compared with the scaled catalytic efficiencies of 43.2 and 20.8 ml/h/g liver for UGT1A6 and UGT1A9, respectively, together with the relative low glucuronidation activity of UGT2B7 at phenol concentrations below 1000 mM (Figure 2 ) which are physiologically relevant, no major contribution of UGT2B7 towards the glucuronidation of phenol in the female human liver was expected.
Both, UGT1A6 and UGT1A9 have a much higher affinity (reflected by a lower K m ) for phenol compared with the other UGT enzymes. Incubations with UGT1A9 with phenol concentrations above 900 mM resulted in substrate inhibition, but this concentration is above phenol plasma concentrations at relevant dose levels. When taking into account the kinetic plots of the UGTs and the scaled catalytic efficiencies which are corrected by the RAF, UGT1A6, and UGT1A9 are estimated to be the UGTs predominantly contributing to the glucuronidation of phenol in the female human liver and these UGTs were thus included in our PBK model to evaluate interindividual differences using Monte Carlo simulations. The CVs of the apparent V max of UGT1A6 and UGT1A9 are 8% and 34%, respectively, and represent the experimental variation. No CVs for human variation in expression of UGT1A6 and UGT1A9 in a human population were experimentally determined in the current study as this would require measurements of specific probe substrates for these enzymes within a large set of individual human liver microsomes, which was beyond the scope of the present study. The observed CV of 79% for the catalytic efficiency for phenol glucuronidation by the individual human liver microsomes (representing both UGT1A6 and UGT1A9 activity) is in line with what would be expected based on the known variation in UGT1A6 (CV ¼ 76%) and UGT1A9 (CV ¼ 55%) as reported by Court (2010) .
To evaluate the performance of the RAF approach to estimate phenol glucuronidation in female human liver, the sum of the scaled catalytic efficiencies of the individual enzymes UGT1A6 and UGT1A9 was compared with the scaled catalytic glucuronidation efficiency that was measured with pooled female human liver microsomes. It can be concluded that the RAF approach performed reasonably well with the sum of the scaled catalytic efficiencies of the individual enzymes UGT1A6 and UGT1A9 predicting 77% of the total catalytic glucuronidation efficiency that was measured with pooled female human liver microsomes.
PBK Modelling, Monte Carlo Simulations and CSAF
Given that in the present study the phenol PBK model was defined with some updated kinetic parameters an updated sensitivity analyses was performed (See Supplementary Data A). This analysis confirmed that especially the kinetics for glucuronidation of phenol in the liver and the oral absorption coefficient ka were parameters that influenced the maximum predicted phenol plasma concentration (C max ).
Two methods were applied to evaluate the influence of interindividual variation in glucuronidation on phenol plasma concentrations in the female human population. At first, variation in phenol plasma levels was determined for a group of 10 human females. With the kinetic constants obtained in the present study for the 10 female subjects, PBK models were developed for each individual female. Figure 3 presents the predicted phenol plasma C max for each female at an oral dose of 25 mg/kg bw obtained with the PBK model. The geometric mean phenol plasma C max of the 10 females is predicted to be 152 mM and the difference between the highest and the lowest C max of phenol is 3.2-fold. The geometric CV of the predicted C max values is 36%. Secondly, a Monte Carlo simulation (n ¼ 9956) was performed at an oral dose of 25 mg/kg bw to evaluate the interindividual variation in phenol plasma concentrations that could occur in a larger female human population, taking interindividual variation in phenol glucuronidation by UGT1A6 and UGT1A9 into account. The distribution of parameters used in the Monte Carlo simulation is included in Table 3 . Figure 3 presents a box and whisker plot visualising the spread in the C max of phenol for this population. The geometric mean phenol plasma C max is 202 mM, which is 1.3-fold higher than the geometric mean for the 10 individuals. The difference between the highest and the lowest phenol plasma C max predicted with the Monte Carlo simulations is 6.8-fold, which is larger than the difference in C max of 3.2-fold observed for the 10 individuals. The geometric CV of the predicted C max values is 31%, which is comparable to the   FIG. 2 . Concentration dependent formation of phenylglucuronide by cDNA recombinant expressed UGT enzymes: A, UGT1A6 (n ¼ 3 6 SD); B, UGT1A7 (n ¼ 2 6 SD); C, UGT1A8 (n ¼ 2 6 SD); D, UGT1A9 (n ¼ 2 6 SD); E, UGT2B7 (n ¼ 3 6 SD).
geometric CV of the 10 individuals. Comparing the phenol plasma C max predicted for the 10 individuals and the Monte Carlo simulations with variation in UGTs, indicates that the small group of 10 individuals reasonably represents the geometric mean phenol plasma kinetics of a large population, but that for defining the outer boundaries of the population distribution which are relevant to identify sensitive individuals, a Monte Carlo simulation appears more appropriate.
In a subsequent step, C max of phenol in the female population at an oral dose of 25 mg/kg bw was calculated with the PBK model linked with the Monte Carlo analysis (n ¼ 9907) that included not only variation in UGT1A6 and UGT1A9 activity but also variation in ka. The distribution of parameters used in the Monte Carlo analysis is included in Table 3 . A box and whisker plot visualising the spread of C max of this analysis is included in Figure 3 , and Figure 4 presents the frequency distribution of the predicted C max of phenol. The geometric mean of the C max of phenol in the simulated population is 194 mM and the median C max in this population is 202 mM. The difference between the highest and the lowest C max value in the simulated population at the dose of 25 mg/kg bw is 15.8-fold. Comparing the Monte Carlo predictions with and without ka as a variable parameter indicates that introducing variation in ka in the Monte Carlo analysis increased the difference between the highest and lowest predicted C max value in the population distribution from 6.8-fold to 15.8-fold. This result also demonstrates that variation in ka provides an important contribution to variation in the population distribution of the C max of phenol. Overall, the Monte Carlo simulation including variation in V max of the UGTs and ka provides the best insight in interindividual differences in the kinetics of phenol.
The data now obtained for the distribution of the plasma C max of phenol in the population can be used to obtain a chemical specific adjustment factor (CSAF) for the interindividual variation in the kinetics of phenol. Such a CSAF can be defined based on the ratio of the 90th or the 99th percentile of the population distribution of the plasma C max of phenol divided by the mean value (IPCS 2005) . For this analysis, the results obtained with Monte Carlo simulations that included variation in UGT1A6, UGT1A9, and ka were first used. The geometric mean, the 90th and the 99th percentiles of the plasma C max of phenol are 194, 303, and 391 mM, respectively. The CSAF thus obtained amounted to 1.6 when using the 90th percentile, whereas the CSAF amounted to 2.0 when the 99th percentile was used thus including even the most sensitive individuals. The CSAF of 2.0 could replace the default uncertainty factor of 3.16 that accounts for interindividual human kinetic differences (IPCS 2005) .
So far the Monte Carlo simulations included variation in the parameters Vmax_UGT1A6, Vmax_UGT1A9, and ka, but to determine a CSAF also a Monte Carlo simulation was performed for all parameters with a sensitivity coefficient > 0.2 (in total 10). In the end, CSAFs were calculated for three different scenarios in which for each scenario the effect of variation of different Could not be derived because of linear kinetics. parameters in the Monte Carlo simulations was included in the analysis (see Table 4 ). The coefficient of variation that was applied for each parameter in the Monte Carlo simulations is specified in the Supplementary Data B. The CSAF when taking into account variation in parameters with a CV > 0.2 in the sensitivity analysis (Scenario 1) differed, both when using the 90th and 99th percentile, only 1.1-fold from the corresponding CSAF when variation in only the V max of UGT1A6, UGT1A9 and ka (Scenario 2) was taken into account. This further supports that the V max of UGT1A6 and UGT1A9 together with ka are parameters that mostly influence the C max of phenol.
Dose-Response Analysis
In an additional step, the PBK models were used to analyse the consequences of the detected interindividual variation in C max values for the predicted in vivo dose-response curves for the developmental toxicity of phenol in human. To this end, the in vitro effect concentrations that were previously obtained with the EST (Strikwold et al. 2012) were converted to in vivo effective doses applying PBK-based reverse dosimetry. First reverse dosimetry was applied using the PBK model for the average female human based on the average kinetic constants derived from the incubations with pooled female human liver microsomes in the present study. The resulting dose-response curve is presented in Figure 5 . The BMDL 05 derived from this dose-response curve of the average female was 27 mg/kg bw and can serve as a PoD for the risk assessment. In a next step, the interindividual variation in V max and ka values was taken into account by dividing the dose-response curve data with the CSAF obtained for the 99th percentile of scenario 2. The curve thus obtained ( Figure 5 ) reflects the consequences of the interindividual variability in phenol kinetics for the ultimate dose-response curve for human developmental toxicity presenting the curve for the most sensitive females in the population.
DISCUSSION
The present study aimed to demonstrate an approach that combines in vitro toxicity data, PBK modelling and Monte Carlo simulations to assess the consequences of human interindividual variation in kinetics for phenol-induced developmental toxicity. The sensitivity analysis of the PBK model for phenol for the average population revealed that especially the oral absorption coefficient (ka) and glucuronidation of phenol in the liver were parameters that influenced the maximum predicted phenol plasma concentration (C max ) and these parameters were therefore included in the evaluation of interindividual variation in the present study. At first, glucuronidation of phenol was determined with 10 individual human female liver fractions and the kinetic constants obtained were used to define individual PBK models for phenol for each female which were used to predict phenol plasma levels. Secondly, to enable prediction of interindividual variation in a larger human population, Monte Carlo simulations were performed in connection with our PBK model for phenol, simulating interindividual human variation on the basis of the conversion of phenol by UGT enzymes and literature reported information on variation in expression of these enzymes. In a final step also variability in the oral absorption coefficient was included in the analyses.
UGT enzymes involved in glucuronidation of phenol have not been fully characterised before. Our studies with Supersomes TM revealed that UGT1A1, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15 are intrinsically able to glucuronidate phenol. Taking the relative expression of these enzymes into account, the present study revealed that UGT1A6 is the primary UGT responsible for the glucuronidation of phenol in the liver followed by UGT1A9, which is in line with the involvement b /h, value obtained from the rat in situ intestinal perfusion study of Humphrey et al. (1980) . of these UGT enzymes in the glucuronidation of a series of p-substituted phenols (Ethell et al. 2002) .
In the present study, variability in phenol glucuronidation was assessed based on in vitro kinetic data obtained with experiments using UGT isoforms and human variation in expression of these UGTs derived from the literature from a human liver bank of 54 people (man and woman) (Court 2010) . Court (2010) did not find any significant effect of gender, age (when age > 20 years) and smoking on the glucuronidation activity in the liver by UGT1A6 and UGT1A9. However, consuming alcohol was associated with an increased glucuronidation of the specific probes serotonin (UGT1A6) and propofol (UGT1A9). Additionally, drug intake, diet or environmental factors (Guillemette 2003 ) may also influence the activity of UGT enzymes as well as genetic polymorphisms. As no gender differences were observed for UGT1A6 and UGT1A9 (Court 2010 ) the reported CVs were considered adequate and used to simulate developmental toxicity in the female population in the Monte Carlo modelling.
Within the present study the focus was on including variability in the most sensitive parameters that influence the model outcome. For this reason, the kinetic constants for glucuronidation of phenol and the oral uptake rate constant were varied in the Monte Carlo simulations. Little information exists on variation in uptake of compounds from the intestine, whereas from our Monte Carlo analysis with and without variation in ka it can be concluded that variation in ka provides an important contribution to variation in the population distribution of C max of phenol. It is expected that oral absorption of the phenols is driven by passive diffusion. Factors like gastric emptying time, gastrointestinal motility, bile secretion, and pH may in general influence passive diffusion (Martinez and Amidon 2002) , and possibly also the pre-systemic intestinal metabolism of compounds. It is unknown, however, if (variation in) these factors give rise to the CV of 30% that was applied in the present study representing a moderate level of variation (Covington et al. 2007 ), or whether the CV of 30% should be considered a worst case approach to model interindividual variability in ka. Further research towards interindividual variation in the oral uptake rate may be undertaken to define a CV representing variation in the human population for this parameter.
The population distribution of the phenol plasma concentration generated by the Monte Carlo simulation including variation in UGT1A6, UGT1A9, and ka provided information to predict a CSAF, which was calculated by the ratio of C max of phenol at the 99th percentile and the geometric mean, resulting in a CSAF of 2.0. Comparing the CSAF of 2.0 derived in the present study to the default uncertainty factor of 10 0.5 (¼3.16) for interindividual human kinetic differences shows that for phenol the default safety factor is adequately protective. The CSAF could replace the default uncertainty factor for interindividual kinetic differences of 3.16 when one would derive a human healthbased guidance value for phenol.
Reverse dosimetry was applied with the PBK model for the average individual providing an in vivo dose-response curve from which a BMDL 05 of 27 mg/kg bw for the average female in the population was derived. When this BMDL 05 is used as a PoD for deriving a health-based guidance value, in addition to the CSAF of 2.0 for interindividual human kinetic differences, also other uncertainty factors may be needed. This includes first of all an uncertainty factor of 10 0.5 (¼3.16) accounting for human variability in toxicodynamics. Furthermore, one could argue that because the extrapolation was based on in vitro toxicity data obtained with cells of animal origin (mouse ES-D3 cells) an additional uncertainty factor of 10 0.4 (¼2.5) should be applied for interspecies differences in toxicodynamics. The default uncertainty factor of 10 0.6 (¼4.0) accounting for interspecies kinetic differences (IPCS 2005) can be omitted because the PBK model for phenol describes the kinetics directly for humans. The total uncertainty factor thus obtained amounts 15.9 and applying this factor to the PoD of 27 mg/kg bw that was derived from the in vivo dose-response curve of phenol for the average female population predicted with in vitro PBK-based reverse dosimetry would provide a guidance value of 1.7 mg/kg bw/day. This value is 3.4-fold higher than the TDI of 0.5 mg/kg bw/day derived from a BMDL 10 of 52 mg/kg bw for maternal toxicity obtained from a developmental toxicity study (Argus 1997) using an overall uncertainty factor of 100 (EFSA 2013) . This difference is mainly due to the use of a CSAF of 2.0 instead of the default value of 3.16 and not applying the uncertainty factor of 4.0 accounting for interspecies kinetic differences because the PBK model for phenol directly applies for humans. Thus, the difference is not caused by the fact that the PoD was derived from an in vitro-PBK based alternative approach, instead of taken from an in vivo developmental toxicity study. It can be argued whether an additional uncertainty factor should be applied to account for uncertainties regarding the use of the in vitro PBK approach, for example regarding differences in sensitivity between an in vitro toxicity assay and an in vivo system towards a test compound and uncertainties that may result from PBK models that are just defined by in vitro and silico predicted input parameters. So far, PoDs for developmental toxicity predicted with the in vitro PBK approach are within a 10-fold difference compared with in vivo reported developmental toxicity PoDs (Louisse et al. 2010 (Louisse et al. , 2014 Strikwold et al. 2013 Strikwold et al. , 2016 . Based on these data it might be advocated to replace the default uncertainty factor of 2.5 for interspecies toxicodynamic differences by a factor of 10 when a PoD is used that is derived with the in vitro PBK approach (when cells from animal origin are used). Applying this uncertainty factor of 10 together with the CSAF of 2.0 for interindividual differences in human kinetics and the uncertainty factor of 3.16 that accounts for interindividual human dynamic differences, provides a total uncertainty factor of 63.2, resulting in a guidance value of 0.43 mg/kg bw/day for phenol which closely resembles the current TDI of 0.5 mg/kg bw/day.
Finally, it is of importance to stress that during pregnancy, biochemical and physiological changes occur which may possibly affect phenol plasma levels. The present study did not explicitly take into account variation in UGT activity during pregnancy, because refining model predictions is not straightforward when the glucuronidation activity changes during the course of pregnancy. However, since results indicate that glucuronidation in humans may increase during pregnancy (Miners et al. 1986 ), phenol plasma levels may be lower than predicted in the current study where the kinetic parameters for the PBK model were determined for the non-pregnant female population for which data and microsomal samples were available. Given that increased glucuronidation will result in lower and thus less toxic plasma levels of phenol it can be concluded that the results obtained are adequately protective.
In conclusion, this study exemplifies a modelling approach to integrate in vitro toxicity data, PBK modelling and Monte Carlo simulations to predict safe human guidance values taking into account interindividual human kinetic variation. The strength of this approach is that it provides a risk assessment that is directly relevant to the human situation, based on only in vitro and in silico data.
SUPPLEMENTARY DATA
Supplementary data are available at Toxicological Sciences online.
FUNDING
This work was supported by the programme Alternatives to Animal Experiments III of the Netherlands Organisation for Health Research and Development (ZonMw) [114011002] .
